MRC1 and colorectal carcinoma: In terms of clinical outcomes, multiple retrospective and prospective series have observed that MMR-deficient CRC—whether sporadic or Lynch-related—tends to confer a better prognosis than MMR-proficient disease, particularly for localized Stage II cancers [17,18].